Sapan Gai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.
It been doing this for a while...its the MM trying to control the system imo... all pretty relevant imo as at some point it needs to go.
Decent rise and pretty small volume granted more than recently, wait until the real volume comes on news, this has a history of spiking hard then settling at multiples of current level.
So undervalued at these prices
Will need some news for that to happen.... and a monthly update of the leads, proposals should be announced to the Market as the comms are crap
Agree - there is defo value down here at these prices
Sorry about 525k
Ah right…Cheers Laura
happy New Year also
Yeah about 750k worth of buys in total
LSE bust? Not showing today’s trades? Been about 750k of buys
Agree on this Laura…pretty obvs with the spread £100 would probs turn it blue haa
Sienna - you have no idea what you are talking about.
The new offices are £50k cheaper than the last ones so downsized
Also you don’t have any shares here and when you did it was 90 quids worth.
Yawn….
What annoys me is they going on like it’s been brilliant…that worries me…. It’s been far from it….
I hope the appointment is a good move but atm I can only see significant costs … presumably they know the pipeline…..
The company needs to have more coms with shareholders and investors and actually answer questions that are presented to them.
I do believe there is contracts on route though
There is massive value down here at these prices…imo
BOD have under delivered absolutely and have let all investors down and as you are probably all aware… it may need a new CEO to build investors confidence again???
But either way there value here absolutely
I'd hope so.... Historically they have.
They have put contract awards out on the 22nd December previously then a few in Jan ????
If you read the link it also mentions project optimus
BT7480 PYC has RNS'd and worked on numerous contracts
BT7480 is a Nectin-4 targeted CD137 agonist designed to overcome immune agonist toxicities and activate the immune system in Nectin-4 expressing tumors. Clinical development has been guided by safety considerations observed with first-generation CD137 agonists, the novelty of the Bicycle® platform technology and the U.S. Food and Drug Administration’s (FDA) Project Optimus initiative. In a Phase 1 clinical trial, BT7480 showed:
In 33 patients assigned to receive one of 9 different doses of BT7480, an emerging differentiated safety and tolerability profile with a low number of severe adverse events. The majority of the patients studied had tumors that expressed Nectin-4 and CD137.
Two unconfirmed partial responses in heavily pre-treated patients with cervical cancer.
Three prolonged stable disease (≥7 months) in NSCLC and anal cancer.
Bicycle Therapeutics will continue to define the recommended Phase 2 dose (or maximum dose) and dose range for BT7480, with a view to enroll combination cohorts with checkpoint inhibitors in 2024. These data will inform the design of a Phase 2 trial that could support potential accelerated approval of BT7480.
Https://www.businesswire.com/news/home/20231214384646/en/Bicycle-Therapeutics-Provides-Data-Updates-for-Three-Clinical-Programs-and-Strategy-Overview-at-First-RD-Day
Great update form Bicycle - All of which PYC has worked/working on - AS they looking to develop these assets towards commercialisation it would indicate in my view PYC will gain further contracts .
Intro - Further info on Link
“During our first R&D Day, we are excited to showcase the advantages of our Nobel Prize-winning science and our strategy to discover and develop therapies with greater tolerability that could provide enhanced benefit to a multitude of patients, starting with those who have cancer,” said Kevin Lee, Ph.D., CEO of Bicycle Therapeutics. “Through our Nectin-4 and EphA2 portfolios and the continued work on our platform, including through partnerships, we are building a leading precision-guided therapeutics company with the potential to address a wide range of diseases that affect millions of people around the world. We believe that our technology has the potential to not only help patients live longer but also to live well.”
“Today we are excited to provide clinical updates for our three lead programs,” said Santiago Arroyo, M.D., Ph.D., Chief Development Officer of Bicycle Therapeutics. “In totality, the data support the emerging differentiated profile of our Bicycle® molecules, paving the way to deliver best-in-class or first-in-class therapies for many cancers. Based on our clinical updates, we are taking important next steps with our development programs, setting up what we expect to be a catalyst-rich 2024.”
VALIPHARMA LTD is also funded by VAL PLC and Owe VAL £2.5 Million ????
Valiseek LTD last accounts is a interesting Read..... Owe VAL PLC a million
With Gerry Desler Invoicing Valiseek LTD from his own company?????
Believe so - they will be giving a business update at the below presentation today...
Just exposure in my view
I would have thought we would have some exposure here as we have work with Bicycle for years on numerous projects...
Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that the company will host its first Research and Development (R&D) Day on Thursday, December 14. The event will take place in New York City from 8 a.m. to 12 p.m. Eastern Time and will be simultaneously webcast.
Bicycle Therapeutics executives will provide investors and analysts with an overview of the company’s R&D strategy and pipeline opportunities, with an emphasis on clinical updates for BT8009, BT5528 and BT7480. The company will also highlight the broad capabilities of its novel Bicycle® platform technology.
Sorry if It’s been posted - Tim Corn one of PYC non exec been made CMO of Oxford Cannabinoid Technologies